Policy & Regulation: Page 14

  • The early morning sun strikes the U.S. Capitol November 6, 2006 in Washington, DC.
    Image attribution tooltip
    Win McNamee/Staff via Getty Images
    Image attribution tooltip

    How Congress could play a role in personalized medicine

    PGx — a tool to help determine proper dosing — may be poised to achieve broader use in healthcare and pharma.

    By Kelly Bilodeau • April 11, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    By Kim Ribbink • April 5, 2022
  • rare disease ribbon Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Rare diseases

    As drug developers find promise in the rare diseases, deals and treatments are on the rise

    By PharmaVoice staff
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

    A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

    By Kelly Bilodeau • March 23, 2022
  • Image attribution tooltip

    Permission granted by Anthony Mack.

    Image attribution tooltip

    Virpax's CEO on leveraging new formulations to move drugs toward approval

    Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.

    By • March 18, 2022
  • Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Image attribution tooltip
    Q&A

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    By Kim Ribbink • March 14, 2022
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip
    Q&A

    Ultragenyx's CEO on building a 'next-gen' rare disease company

    How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

    By Kim Ribbink • March 9, 2022
  • Image attribution tooltip

    Permission granted by Russell Potterfield.

    Image attribution tooltip
    Profile

    From angel to operator: The unlikely journey of Endevica Bio's CEO

    Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

    By Jared Whitlock • March 9, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    QSAM's rare cancer treatment could be a game-changer

    For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.

    By Alexandra Pecci • Feb. 17, 2022
  • Pharma Voice logo
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip

    Welcome to the new PharmaVoice

    A similar mission, a new format, and our plans for PharmaVoice's next chapter.

    By Davide Savenije • Jan. 13, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images
    Image attribution tooltip

    5 trends shaping clinical trial regulations in 2022

    As agencies respond to innovations in pharma, notable shifts in 2022 are on the way.

    By • Jan. 11, 2022
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip
    Profile

    Regulators

    Navigating the regulatory landscape, while ensuring quality and transparency, requires skillful leadership and knowledge. The rebel in the room, doesn’t stay in her lane Blazing new trails to… continue to elevate the need for equity in healthcare Amanjot Kaur Khera Title: ...

    By PharmaVoice Team • Aug. 1, 2021
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Getting Real with RWE

    Real-world evidence, important for regulatory decision-making, is beginning to touch all areas of the healthcare value chain. Historically, real-world evidence (RWE) and real-world data (RWD) have been used for postmarket safety monitoring, but now sponsors are beginning to use these data sets to...

    By Taren Grom • Nov. 16, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The New Virtual Engagement Reality

    COVID-19 has created a virtual environment that is here to stay, and the industry will need to begin to adjust. From remote working to patient and physician engagement, pharma marketers and sales reps have had to rethink commercial strategies in a virtual landscape. With the onset of COVID, the s...

    By Robin Robinson • Nov. 16, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's Next Post-COVID-19: The Next Normal

    From R&D to commercial operations, stakeholders across the healthcare ecosystem are adjusting to the next phase of the pandemic: business in a new reality. With some experts predicting that the “normalization" of business operations could be several months to a year away as the world awaits a...

    By PharmaVoice Team • Sept. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Commanders & Chiefs

    These forward-thinking leaders are strategically positioning their companies for success and inspiring their teams to achieve far-reaching goals as they navigate complex industry challenges. Dr. Reshma Kewalramani Breaking Barriers Raising the bar… by making the impossible, possible. Title: CEO a...

    By PharmaVoice Team • Aug. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Entrepreneurs

    These visionary leaders recognized an opportunity to fill an industry need and are successfully leading their companies to new heights. Game Changer Raising the bar… by proving what is possible in accelerating clinical drug development Michelle Longmire, M.D. Title: CEO and Co-Founder Company: Me...

    By PharmaVoice Team • Aug. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Change Agents

    These forward-thinking individuals are disrupting the status quo and setting the strategic direction for their companies to capitalize on the opportunities that will shape the future of the healthcare ecosystem. Answering the Innovator’s Dilemma Raising the bar… by knowing what is achievable Crai...

    By PharmaVoice Team • Aug. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Patient Champions

    These patient-focused leaders are re-imagining what patient engagement is and what it can be for their organizations and the industry at large. Going the Extra Mile for Rare Disease Patients Raising the bar… to be better than the day before Mary Frances Harmon Title: Senior VP, Corporate and Pati...

    By PharmaVoice Team • Aug. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Mentors

    These champions of diversity and inclusion are dedicated to developing the next generation of leaders and setting an example for others to follow. An Ally for All Raising the bar… by bringing people together Peter Anastasiou Title: Executive VP & Head of North America Company: Lundbeck Indust...

    By PharmaVoice Team • Aug. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    A New Era of Clinical Trials

    The future is now, and how the industry responds to the COVID-19 pandemic will set the course for drug development for years to come. The COVID-19 pandemic has created disruption across every aspect of the world. The clinical trial ecosystem is no exception — from drug discovery through to regula...

    By PharmaVoice Team • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Age of the Machine: Using Algorithms to Advance Outcomes

    Machine learning is being applied across the industry to support decision-making in clinical trials, R&D, regulatory, and commercial processes. What’s the difference between machine learning and artificial intelligence? The answer lies in the word intelligence, since AI is about enabling mach...

    By Kim Ribbink • June 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Clinical Experts

    These clinical development experts are redefining clinical operations to increase efficiencies, reduce costs and timelines, and improve the safety profiles of bringing new medicines to patients. A Rare Passion for Patients Energetic. Unrelenting. L. Mary Smith, Ph.D. Title: Senior VP, Clinical R&...

    By PharmaVoice Team • Aug. 1, 2019
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Brand Bonds

    Trust is the glue of agency/client relationships, and communication is the foundation. Browse a few pharma marketing agency websites and you can learn about the number of awards won, the big name clients, the years in business, the expertise; but where is the link for “Good at Relationships?" One...

    By PharmaVoice Team • May 1, 2019
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Patient-Based Culture

    Companies need to cultivate patient-centricity from the inside out. Not much more than five years ago, UCB was one of the first pharma companies to bring patient centeredness deep into its culture, moving away from the traditional product-based model driven by revenue growth and sales toward the ...

    By PharmaVoice Team • April 1, 2019
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Evolving Role of Patient Advocates

    Patient advocacy groups have long had relationships with pharma, and now, individual patients are also sharing their voices and their power. While pharma has long had relationships with advocacy organizations, there is a growing wave of individual patients who are willing to speak up, be engaged,...

    By PharmaVoice Team • April 1, 2019